Vas Narasimhan

Chief Executive Officer - Novartis AG

Photo: World Economic Forum, CC BY 3.0 (Wikimedia Commons, cropped)

Headlines and summaries are written by AI. How it works

Jul 22
Novartis returns to growth in Q2 as new cancer drugs offset 50% Entresto slump
Newer drugs Kisqali and Pluvicto drove a 36% revenue surge to nearly $7 billion, helping the Swiss pharma group post $14.4 billion in sales and stable core profit of $5.94 billion.